Linkage Of Patient Services and Real-world Healthcare Data: A Unique Approach to Gain Insights into Factors that Impact Medication Adherence
Author(s)
Samuel Igweokpala, MSc1, Irene Pan, MSc2, irene cosmatos, MSc2.
1United BioSource LLC (UBC), King of Prussia, PA, USA, 2United BioSource Corporation, King of Prussia, PA, USA.
1United BioSource LLC (UBC), King of Prussia, PA, USA, 2United BioSource Corporation, King of Prussia, PA, USA.
Presentation Documents
OBJECTIVES: Patient services are support programs sponsored by pharmaceutical companies to improve patient access and adherence to prescribed therapies. Access and adherence to prescribed therapies is a primary goal of patient service programs; however, limited real-world claims data can prevent meaningful assessments of the impact a patient services program is providing. This research describes the novel, privacy-preserving approach of tokenizing patients in a support program to obtain their real-world data to gain insights into factors that influence drug adherence.
METHODS: Using Datavant’s patient tokenization, this retrospective cohort study identified pharmacy and medical claims from Komodo’s Healthcare Map (KHM) between November 2019 and September 2024 for patients in a patient support program for a novel therapy for a hematological disease. Medication adherence, overall, within the program and outside the program and by distribution channel, for 12 months after therapy initiation, was estimated in patients with at least 2 dispenses using the proportion of days covered (PDC) measure.
RESULTS: Tokenization of 8,496 patients in the program resulted in a match with 8,159 patients in KHM (a 96% overlap). Of these 8,159 patients, 1,128 (14%) filled at least 2 prescriptions for the novel therapy. The majority filled their prescriptions through specialty pharmacies (91%). The mean (SD) PDC was 0.82 (0.20) for these patients. Notably, over one-third of patients did not achieve the generally accepted good adherence standard of PDC>0.80.
CONCLUSIONS: Our study showed that data linkage between patient support programs and real-world data sources is highly feasible and offers a way to enrich longitudinal data for practical analyses while maintaining patient privacy. Further analyses will explore potential factors that contribute to poor adherence in this patient population, such as comorbidities, insurance type and adverse outcomes. The impact of participation in the patient service program will be evaluated.
METHODS: Using Datavant’s patient tokenization, this retrospective cohort study identified pharmacy and medical claims from Komodo’s Healthcare Map (KHM) between November 2019 and September 2024 for patients in a patient support program for a novel therapy for a hematological disease. Medication adherence, overall, within the program and outside the program and by distribution channel, for 12 months after therapy initiation, was estimated in patients with at least 2 dispenses using the proportion of days covered (PDC) measure.
RESULTS: Tokenization of 8,496 patients in the program resulted in a match with 8,159 patients in KHM (a 96% overlap). Of these 8,159 patients, 1,128 (14%) filled at least 2 prescriptions for the novel therapy. The majority filled their prescriptions through specialty pharmacies (91%). The mean (SD) PDC was 0.82 (0.20) for these patients. Notably, over one-third of patients did not achieve the generally accepted good adherence standard of PDC>0.80.
CONCLUSIONS: Our study showed that data linkage between patient support programs and real-world data sources is highly feasible and offers a way to enrich longitudinal data for practical analyses while maintaining patient privacy. Further analyses will explore potential factors that contribute to poor adherence in this patient population, such as comorbidities, insurance type and adverse outcomes. The impact of participation in the patient service program will be evaluated.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH185
Topic
Epidemiology & Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)